Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Approval Highs And Lows For Leading Japanese Pharma; Dogged By Competitors And Nagging Supply Issues

This article was originally published in PharmAsia News

Executive Summary

TOKYO - Japanese pharma Eisai, Daiichi Sankyo and Mitsubishi Tanabe have had a rough seven days despite last week's slate of new drug approvals in Japan. Those approvals were capped with Mitsubishi Tanabe recalls and Eisai's discontinuation of a key Phase III trial

You may also be interested in...



Daiichi Sankyo Gains First Approval For Oral Factor Xa Inhibitor In Japan

TOKYO - Daiichi Sankyo Co. Ltd. received official approval for the first oral Factor Xa inhibitor in Japan. Following a recommendation for approval in March, Japan's Ministry of Health, Labor and Welfare approved Lixiana (edoxaban) for prevention of post-surgery thromboembolism April 22

Daiichi Sankyo Gains First Approval For Oral Factor Xa Inhibitor In Japan

TOKYO - Daiichi Sankyo Co. Ltd. received official approval for the first oral Factor Xa inhibitor in Japan. Following a recommendation for approval in March, Japan's Ministry of Health, Labor and Welfare approved Lixiana (edoxaban) for prevention of post-surgery thromboembolism April 22

Daiichi Sankyo Gains First Approval For Oral Factor Xa Inhibitor In Japan

Boehringer Ingelheim's Pradaxa has set the bar by showing superiority to standard-of-care warfarin, and Daiichi Sankyo has staked a lot on an ongoing Phase III comparison study of Lixiana (edoxaban) to warfarin for the prevention of thromboembolism in atrial fibrillation, expected to report in 2012.

Related Content

UsernamePublicRestriction

Register

ID036688

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel